← board
CUBT
distress 5/10 · elevated risk$1.03+26%today-47% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
—
Price & events
-1.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+26.1%
1D
+3.4%
1W
-22.4%
1M
+4.8%
3M
-1.0%
6M
-28.9%
1Y
-54.9%
2Y
-93.3%
5Y
-77.4%
All
Overview
- Volume
- 2.87K
- 52 Week Range
- $0.65 – $1.94
- Float Shares
- 5.73M
- % Held by Insiders
- 0.04%
- % Held by Institutions
- 0.00%
- RVOL
- 3.44x
- Beta
- 1.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- 2025-08-01S-1/Ashelf_registration
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.